Antihypertensive monotherapy, although commonly used, does not address the multifactorial nature of hypertension as a disease with many pathways. Using more than one drug makes more therapeutic sense because combination agents cover more than one pathway, yet the use of drugs in tandem is typically relegated to more problematic patients later in therapy. Many patients with hypertension are not controlled, because the monotherapeutic agent is used at its highest dose, resulting in side effects that lead to noncompliance. As opposed to fixed-dose combinations that merge two drugs at their highest doses, low-dose combination therapy provides more novel coverage of two or more metabolic pathways that contribute to hypertension. Their once-daily dosing encourages compliance. In addition, because the two drugs are combined at low doses, the probability of side effects is decreased and efficacy is often enhanced. The use of low-dose combination antihypertensive agents is a good contemporary strategy for first-line therapy in that patients can take advantage of their cardiovascular benefits and the control these agents offer early in therapy. Am J Hypertens 1999; 12:73S-79S
pidemiologic studies have demonstrated that although the risk of stroke among hypertensive patients has decreased significantly, the reduction in coronary artery disease (CAD) has been disappointing. There are probably several reasons for this; however, poor blood pressure control remains among the most important. Of all people with hypertension in the United States, only 73% are aware of their condition and only 55% are undergoing treatment for it. Of those being treated for hypertension, about half are controlled to a level of less than 140/90 mm Hg. 1 These inadequately controlled hypertensive patients are at significant risk for developing cardiovascular disease. Data from the Multiple Risk Factor Intervention Trial (MRFIT), a study that described the relationship between blood pressure and death from coronary heart disease (CHD) in men with a history of myocardial infarction, showed a positive association between systolic blood pressure and death from CHD. After 2 years of followup, both CHD and all-cause mortality rates were about 40% higher for study subjects with systolic blood pressures (SBP) of 140 mm Hg or higher than for subjects with SBP less than 140 mm Hg, regardless of diastolic blood pressure. 2 The association of CHD mortality with inadequately controlled blood pressure is strengthened when the patient has additional car-diovascular risk factors, such as high cholesterol or a history of cigarette smoking. Increased efforts need to be made in controlling blood pressure to reduce the risk for subsequent cardiovascular events. This paper cites the various reasons why patients have difficulty controlling their hypertension with monotherapy, as well as the benefits of low-dose combination therapy, both from an efficacy and side-effect standpoint. The combination therapy strategy assists patients in reaching their optimal blood pressure goals and may be an attractive alternative for first-line use or much earlier use in the management of arterial hypertension.
REASONS BEHIND INADEQUATE BLOOD PRESSURE CONTROL
In excess of 70 medications exist for the treatment of hypertension. Yet the majority of patients with high blood pressure are not controlled to 140/90 mm Hg. When the goal for treating hypertension is reduced to 125/75 mm Hg, as recommended by the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI), 3 for patients with renal insufficiency, the number of uncontrolled patients soars. Why are so few people controlled?
Patient Compliance Lack of patient compliance is an important cause of inadequate blood pressure control. About half of all such treatment failures at the patient level are related to factors such as cost and adverse effects of medication, complex drug regimens, failure of clinicians to be aggressive enough in achieving adequate control, and lack of patient education. 4 The factors that contribute most to noncompliance are the side-effect profile of the antihypertensive product and convenience of the dosing schedule.
For example, when the dosing frequency is once daily, the compliance rate is about 84%. When dosing is twice daily, compliance falls to 75%. Thrice-daily dosing regimens cause compliance to fall to 59%. 5, 6 Thus, the ideal medication would be one that is given once daily.
Side-Effect Profile
Much of poor patient compliance can be blamed on the side effects the antihypertensive medication causes. This factor must be dealt with to achieve blood pressure control. With the large number of drugs available, a drug with a favorable side-effect profile can be found for the vast majority of hypertensive patients. Most side effects with antihypertensive agents are dose dependent. Using smaller doses of various drugs limits dose-dependent side effects. Patients may report their adverse event to the physician but frequently may respond by not taking their medication or by taking it irregularly. The physician must actively question the patient with regard to tolerability, and change or decrease the dose if side effects are a problem.
Convenience Reduction in the number and frequency of drug doses may improve antihypertensive medication compliance. 5, 6 Although once-a-day dosing is presently the ideal dosing frequency, the antihypertensive agent used must demonstrate true 24-h effect. The risk of nonembolic stroke and myocardial infarction is not randomly spaced throughout the day, but peaks in the early morning and coincides with the sudden blood pressure surge that occurs upon awakening. 7 Therefore, a drug taken once daily in the morning may not protect the patient at the time of day when he or she is at most risk for experiencing a cardiovascular event. Measuring blood pressure in the clinic at drug trough, that is, 24 to 26 h after the last dose, will indicate whether the drug provides 24-h blood pressure control. If blood pressure is high at the end of the dosing interval, the medication should be switched or dosed twice daily.
Hypertension is a Multifactorial Disease
Hypertension is a multifactorial disease in which many systems interact and lead to the increase in blood pressure. Thus, only 40% to 50% of hypertensive patients will respond to any class of monotherapy. 8 The combination of two complementary agents improves the response rate because more than one physiologic pathway is interrupted. Patients who are still not controlled with two drugs will require a third or even fourth drug added to their regimen to achieve control.
New Blood Pressure Goals Strive for Lower Readings
Lower blood pressures are associated with fewer cardiovascular events. 2, 9 Hypertensive patients with diabetes have even more to gain by controlling their blood pressures. 9 For patients with renal insufficiency and proteinuria, the most significant renoprotective effects occur in patients with lower blood pressures. 10 In response to these data, the JNC now classifies a sphygmomanometer reading of 130 to 139 mm Hg (systolic) or 85 to 89 mm Hg (diastolic) as high-normal and a blood pressure of less than 130/85 mm Hg as normal. 3 Patients with coronary artery disease should aim for a blood pressure goal of 120/80 mm Hg. A diabetic patient with nephropathy should consider a reading of 125/75 mm Hg as most ideal. 3 As discussed earlier, only half (ie, 27.5%) of patients treated for hypertension are controlled at blood pressure goals of 140/90 mm Hg (see earlier). New lower blood pressure goals may widen the gap between treatment and control rates.
Physicians Do Not Always Titrate Antihypertensive
Medication A study that involved more than 11,000 European patients with hypertension showed that almost two-thirds were not adequately controlled on their medication, and that, in 82% of the cases, the physicians involved took no action. 11 The main reasons physicians gave for their reluctance to change the regimen were their concerns about increased side effects with a higher dose, adverse metabolic consequences, higher medication costs, and patient resistance to polypharmacy or higher doses.
This study suggests that patients will be better served if they are encouraged to achieve adequate blood pressure control early in their therapy. Combination therapy used early in the treatment process may improve blood pressure control rates.
RATIONALE FOR THE STEPPED-CARE APPROACH MAY BE QUESTIONABLE
The stepped-care approach in managing hypertension is currently recommended by JNC VI 3 and is the strategy generally favored by clinicians. However, the approach often fails in the nonpharmacologic treatment phase and in step 1 because many patients will not succeed in making lifestyle changes, and will not be adequately controlled with monotherapy. The rationale for the stepped-care approach is based on the premise that, compared with combination therapy, monotherapy is more convenient, better tolerated, less costly, and permits easier identification of side effects should they occur. This premise is not entirely sound.
Is Monotherapy More Convenient Than Low-Dose
Combination Therapy? No. There are several lowdose combination formulations available where one pill is taken once daily (Table 1 ). These formulations are as convenient as monotherapy.
Is Monotherapy Better Tolerated?
No. Although 50% of all hypertensive patients respond to monotherapy, many of them (Ϸ2/3) require the highest recommended dose to achieve control. 8, 12 Because most side effects are dose dependent, successful monotherapy at high doses has an increased risk of adverse events. Low-dose combination agents, because of each agent's additive effect on blood pressure, would expose the patient to fewer side effects and would provide the same or better blood pressure control.
Is Monotherapy Less Costly?
No. Two-drug therapy is expensive in that there are two copayments, two dispensing fees, the cost of titrating two drugs, and the cost of the two drugs themselves. High-dose monotherapy may also be expensive because of visits for increased side effects, laboratory tests needed to confirm adverse events, and the added cost of using twice the amount of medication to control the person using one drug. In contrast, low-dose combination therapy involves less titration, as well as one copayment, one dispensing fee, and a drug price that is 
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typically less than if the two components were used separately. It should be remembered that the cost of treating hypertension is not simply the cost of the drug, but includes general office visits, visits for adverse events, laboratory tests, costs associated with poor compliance in terms of mortality and morbidity, and dissatisfied patients.
Is Monotherapy Less Problematic When Side Effects Occur?
No. Most of the side effects that are usually associated with the antihypertensive drugs commonly used are typically drug specific. An example is the cough caused by angiotensin-converting enzyme (ACE) inhibitors. Discontinuing a combination drug because of an adverse event is no more complicated than discontinuing a single drug for the same reason. Thus many of the reasons for using the stepped-care approach need to be reconsidered. Low-dose combination therapy is an attractive alternative in the management of hypertension.
BENEFITS OF LOW-DOSE COMBINATION THERAPY
Benefits of low-dose combination therapy are outlined in Table 2 .
Improved Efficacy Using small doses of complementary antihypertensive agents can result in additive blood pressure reductions frequently greater than those resulting from larger doses of the agents used alone. 12, 13 This improved efficacy is the result of the complementary action of the two agents (Table 3) . 14 In addition, more rapid blood pressure control may be attained, which may be important given that physicians are reluctant to titrate.
Enhanced Response Rate
Because of the complementary action of antihypertensive agents in combination therapy, response rates are greater than those seen with each of the components. In a multicenter, double-blind, randomized parallel-group study, patients with essential hypertension were given either an ACE inhibitor, a calcium channel blocker (CCB), or a combination of the two. Responses were defined as a mean sitting diastolic blood pressure less than 90 mm Hg or a greater than or equivalent to 10-mm Hg decrease from baseline. A responder rate of 87% was seen in the combination group, as opposed to 68% in the calcium channel blocker group, 54% in the ACE inhibitor group, and 16% in the placebo group (P Յ .005).
14 Adverse Events are Minimized Low-dose combination therapy results in fewer adverse events in addition to greater blood pressure reduction. Many of the dose-related adverse events experienced when using monotherapy can be minimized when the drug is used at a lower dose and in combination with another low-dose drug. For instance, peripheral edema is a common side effect of calcium channel blockers that is produced by unopposed vasodilation of the arterial system. This results in increased capillary hydrostatic pressure, development of a capillary leakage syndrome, and peripheral edema. Conversely, ACE inhibitors cause vasodilation in both the arterial and venous systems. Adding an ACE inhibitor to a calcium channel blocker reduces the pressure in the capillary bed, thereby reducing the potential for peripheral edema (Figure 1 ).
14 Thus a combination of an ACE inhibitor and calcium channel blocker provides greater efficacy and a side-effect profile that is similar to the ACE component and has less edema than the CCB component.
14 Metabolic Effects are Lessened Antihypertensive drug-related metabolic effects, such as hypokalemia, hypoglycemia, and increased low-density lipoproteins, are also dose dependent. Agents such as diuretics and ␤-blockers, when given in higher doses, may have a negative effect on these parameters as opposed to using them in smaller doses, which may actually 
LOW-DOSE COMBINATION AGENTS ARE COST-EFFECTIVE
Studies show that low-dose combination agents are cost-effective. In one retrospective cost-effectiveness analysis of a calcium channel blocker/␤-blocker combination versus an ACE inhibitor used singly, the costs per mm Hg reduction and per patient reaching target diastolic blood pressure goals after 8 weeks of therapy were 40% and 34% lower in the combination group, respectively. 15 In a cost-containment analysis, the cost for the combination ACE inhibitor/calcium channel blocker (benazepril-amlodipine) was compared with costs for separately prescribed ACE inhibitors and CCB in 219 Medicaid patients. 16 This combination (benazepril-amlodipine) was Ϸ 1 ⁄3 the monthly cost of other separately prescribed ACE and CCB combinations.
OUTCOME DATA
Studies have suggested that lower blood pressures are associated with favorable cardiovascular outcomes. The cardiovascular protective effect of low-dose combination therapy exceeds that of higher-dose monotherapy, as evidenced by clinical studies. The Hypertension Optimal Treatment (HOT) trial showed that patients in the diastolic less than 80 mm Hg group, in particular those patients with diabetes, had a lower cardiovascular mortality than patients in the diastolic less than 90 mm Hg group. 9 As demonstrated in Figure 2 , the reductions in systolic and diastolic blood pressure were extremely large (Ͼ 20 mm Hg reduction) for all three subgroups. An important insight gained from the HOT trial was the realization that when guided by a protocol, physicians can achieve adequate blood pressure control. Also notable is that although adequate blood pressure control was achieved, accomplishing control with a single drug is difficult. For example, of those who were still taking a calcium channel blocker at the study's end, 45% were also taking an ACE inhibitor and 32% were also taking a ␤-blocker to achieve target blood pressure. 9 Data from the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) 17 demonstrated that hypertensive patients with diabetes who were treated with an ACE inhibitor had fewer cardiovascular events than patients treated with a calcium channel blocker. However, approximately one-third of patients required an ACE inhibitor plus a calcium channel blocker for blood pressure control. Data from this study suggest that individuals treated with an ACE inhibitor and calcium channel blocker had fewer cardiovascular events than individuals treated with ACE inhibitor monotherapy. Moreover, this study was not powered for cardiovascular events; larger studies powered to detect a difference in cardiovascular events among treatment groups are needed to confirm these findings.
A study comparing the renoprotective effects of an ACE inhibitor, nondihydropyridine calcium channel blocker, or both, in patients with diabetic nephropathy demonstrated that both agents as monotherapy protected the kidneys and reduced proteinuria. However, the combined use of the ACE inhibitor and calcium channel blocker had a superior renoprotective effect with greater reductions in proteinuria than either agent alone. 18 This greater reduction in proteinuria may also be related to the greater blood pressure reduction seen in the patients using combination therapy. 14 Am, amlodipine; Bz, benazepril.
FIGURE 2.
Blood pressure reductions for the three subgroups of the HOT study. 9 DBP, diastolic blood pressure; BP, blood pressure.
LOW-DOSE COMBINATIONS ARE AN ATTRACTIVE FIRST-LINE TREATMENT MODALITY
To be considered as first-line therapy, low-dose combination antihypertensive agents (Table 1) must prove in multifactorial studies that they are more effective and have fewer side effects than each of the component agents. Except for bisoprolol/hydrochlorothiazide and captopril/hydrochlorothiazide, the available combination agents have been given a second-line indication because they have a side-effect profile similar to one of their component agents. For example, a combination ACE inhibitor/calcium channel blocker generally has a side-effect profile that is slightly better than a calcium channel blocker alone because of a lower incidence of peripheral edema. But because the cough induced by the ACE inhibitor is not dose dependent, the combination has a side-effect profile similar to that of an ACE inhibitor used as monotherapy and is thus indicated as a second-line agent. Low-dose combination drugs should be distinguished from fixed-dose combination drugs-such as atenolol/ chlorthalidone-that merge two agents at each of their highest recommended doses in one dosage form for convenience. This usually does not have the desired impact on the side-effect profile because of the higher doses in these combinations. Low-dose combination drugs produce additive hypotensive effects, but because they are comprised of submaximum doses, the side-effect profile is frequently much better than that seen with similar or higher doses of monotherapy.
CONCLUSION
The fact that large numbers of people with hypertension are not controlled makes the need for alternative modalities obvious. Combination therapy has traditionally only been considered as an option late in the course of the management of hypertension. However, with the development of low-dose combination agents, the main reasons for using combination therapy later in the course of treating hypertension may no longer apply. The greater safety profiles, improved efficacy, enhanced response rates, and lack of effect on metabolic parameters make low-dose combination therapy an attractive alternative for first-line use.
